Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Khan, Takeshi Tsuda, Patrick Chames, Javier Lacadena, Luis Álvarez-Vallina, Laura Sanz
{"title":"将 T 细胞定向策略与阻断 TGF-β 和 PD-L1 的双特异性抗体相结合可增强抗肿瘤反应","authors":"Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Khan, Takeshi Tsuda, Patrick Chames, Javier Lacadena, Luis Álvarez-Vallina, Laura Sanz","doi":"10.1080/2162402x.2024.2338558","DOIUrl":null,"url":null,"abstract":"T cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor micr...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"28 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses\",\"authors\":\"Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Khan, Takeshi Tsuda, Patrick Chames, Javier Lacadena, Luis Álvarez-Vallina, Laura Sanz\",\"doi\":\"10.1080/2162402x.2024.2338558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"T cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor micr...\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2024-04-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402x.2024.2338558\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2024.2338558","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
T cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor micr...
期刊介绍：
Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy.
While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
